The latest price of the first generic dabrafenib/dabrafenib in Laos

Dabrafenib is a targeted therapy for certain mutated types of melanoma, non-small cell lung cancer, and thyroid cancer. It is understood that there are several Laotian versions of dabrafenib generics on the overseas market. Common manufacturers may include Laos Lucius Pharmaceuticals, Daxiong Pharmaceuticals, Second Pharmaceutical Factory, etc. The drugs they produce are basically the same as the original drugs in terms of drug ingredients and efficacy, but there are some differences in manufacturers or prices.

Dabrafenib, also known as Teferal, is a targeted anti-cancer drug developed and produced by Novartis. It is primarily used to treat certain types of cancer with BRAF V600E or V600K gene mutations, including unresectable or metastatic malignant melanoma, non-small cell lung cancer, and certain types of thyroid cancer. Dabrafenib inhibits the abnormal signaling pathways produced by BRAF gene mutations, thereby inhibiting the growth and spread of tumor cells and achieving the purpose of treating cancer. Dabrafenib is specially designed for cancer patients with specific genetic mutations. Its efficacy and safety have been verified in cancer patients. Common side effects may include but are not limited to skin lesions, fever, fatigue, joint pain, headache, nausea, vomiting, diarrhea, rash, high blood sugar, etc., and may even increase the risk of malignant tumors such as skin cancer.

Currently, the Laotian version of the generic version of Venacla is not available in the country and may be sold in local hospitals in Laos. Taking a box of 100mg*112 tablets as an example, the price of each box may range from RMB 2,000 to more than RMB 3,000 (the price may fluctuate due to the exchange rate). For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.